rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-638-641rsp-3256Research ArticleСтатьиArticlesРезолюция Совета экспертов (16 июня 2022 г.): Терапия подагрического артрита ингибитором ИЛ-1 (анакинра)Resolution of the Council of Excperts (16th June, 2022): Therapy of gouty arthritis with an IL-1 inhibitor (anakinra)https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.https://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.202226122022606638641Copyright © Насонов Е.Л., Елисеев М.С., 20222022Насонов Е.Л., Елисеев М.С.Nasonov E.L., Eliseev M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3256
.
.
ReferencesНасонов ЕЛ, Самсонов МЮ. Роль интерлейкина 1 в развитии заболеваний человека: фокус на анакинре (рецепторном антагонисте ИЛ-1). Научно-практическая ревматология. 2022;60(3):280-298. doi: 10.47360/1995-4484-2022-280-298Nasonov EL, Samsonov MYu. The role of interleukin 1 in the development of human diseases: Focus on Anakinra (IL-1 receptor antagonist). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(3): 280-298 (In Russ.)]. doi: 10.47360/1995-4484-2022-280-298Kineret (package insert). Thousand Oaks (CA):Amgen Inc.;2001.Kineret (package insert). Thousand Oaks (CA):Amgen Inc.;2001.Насонов ЕЛ, Елисеев МС. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2016;54(1):60-77. doi: 10.14412/1995-4484-2016-60-77Nasonov EL, Eliseev MS. Role of interleukin 1 in the development of human diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2016;54(1): 60-77 (In Russ.)]. doi: 10.14412/1995-4484-2016-60-77FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1):29-42. doi: 10.1136/annrheumdis-2016-209707Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1):29-42. doi: 10.1136/annrheumdis-2016-209707So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. doi: 10.1186/ar2143So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. doi: 10.1186/ar2143Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: Report of ten cases. Semin Arthritis Rheum. 2010;40(3):210-214. doi: 10.1016/j.semarthrit.2010.03.001Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: Report of ten cases. Semin Arthritis Rheum. 2010;40(3):210-214. doi: 10.1016/j.semarthrit.2010.03.001Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-1384. doi: 10.1002/acr.21989Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-1384. doi: 10.1002/acr.21989Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: A retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. doi: 10.1186/ar4303Ottaviani S, Moltó A, Ea HK, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: A retrospective study of 40 cases. Arthritis Res Ther. 2013;15(5):R123. doi: 10.1186/ar4303Van Wabeke J, Dhondt E, Peene I, Piette Y. Anakinra in resistant gout: A case report. Acta Clin Belg. 2017;72(4):293-295. doi: 10.1080/17843286.2016.1239891Van Wabeke J, Dhondt E, Peene I, Piette Y. Anakinra in resistant gout: A case report. Acta Clin Belg. 2017;72(4):293-295. doi: 10.1080/17843286.2016.1239891Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystalinduced arthritis in complex hospitalized patients: A case series and review of the literature. Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173Aouba A, Deshayes S, Frenzel L, Decottignies A, Pressiat C, Bienvenu B, et al. Efficacy of anakinra for various types of crystalinduced arthritis in complex hospitalized patients: A case series and review of the literature. Mediators Inflamm. 2015;2015:792173. doi: 10.1155/2015/792173Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015;45(1):81-85. doi: 10.1016/j.semarthrit.2015.02.006Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015;45(1):81-85. doi: 10.1016/j.semarthrit.2015.02.006Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M. Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol. 2015;34(5):981-984. doi: 10.1007/s10067-014-2601-7Vitale A, Cantarini L, Rigante D, Bardelli M, Galeazzi M. Anakinra treatment in patients with gout and type 2 diabetes. Clin Rheumatol. 2015;34(5):981-984. doi: 10.1007/s10067-014-2601-7Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: A randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, et al. Anakinra for the treatment of acute gout flares: A randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402Елисеев МС, Черемушкина ЕВ, Красненко СО, Аристова МВ. Применение анакинры у пациента с сочетанием болезни депонирования кристаллов пирофосфата кальция и подагры (клинический случай). Медицинский алфавит. 2022;15(9)6:14-19. doi: 10.33667/2078-5631-2022-15-14-19Eliseev MS, Cheryomushkina EV, Krasnenko SO, Aristova MV. Use of anakinra in treatment of combination of calcium pyrophosphate deposition desease and gout (clinical observation). Medical Alphabet. 2022;15(9)6:14-19 (In Russ.)]. doi: 10.33667/2078-5631-2022-15-14-19Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187(9):4835-4843. doi: 10.4049/jimmunol.1102048Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187(9):4835-4843. doi: 10.4049/jimmunol.1102048Boraschi D, Italiani P, Weil S, Martin MU. The family of the interleukin-1 receptors. Immunol Rev. 2018;281(1):197-232. doi: 10.1111/imr.12606Boraschi D, Italiani P, Weil S, Martin MU. The family of the interleukin-1 receptors. Immunol Rev. 2018;281(1):197-232. doi: 10.1111/imr.12606Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8-27. doi: 10.1111/imr.12621Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8-27. doi: 10.1111/imr.12621Roberge CJ, de Médicis R, Dayer JM, Rola-Pleszczynski M, Naccache PH, Poubelle PE. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol. 1994;152(11):5485-5494.Roberge CJ, de Médicis R, Dayer JM, Rola-Pleszczynski M, Naccache PH, Poubelle PE. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol. 1994;152(11):5485-5494.Pascart T, Norberciak L, Ea HK, Graf S, Guggenbuhl P, Lioté F. Difficult-to-treat gout flares: Eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford). 2019;58(12):2181-2187. doi: 10.1093/rheumatology/kez203Pascart T, Norberciak L, Ea HK, Graf S, Guggenbuhl P, Lioté F. Difficult-to-treat gout flares: Eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford). 2019;58(12):2181-2187. doi: 10.1093/rheumatology/kez203Arnold DD, Yalamanoglu A, Boyman O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front Immunol. 2022;13:888392. doi: 10.3389/fimmu.2022.888392Arnold DD, Yalamanoglu A, Boyman O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front Immunol. 2022;13:888392. doi: 10.3389/fimmu.2022.888392Елисеев МС, Барскова ВГ, Насонов ЕЛ. Канакинумаб (ингибитор интерлейкина 1β) – прорыв в возможностях противовоспалительной терапии при подагре. Научно-практическая ревматология. 2013;51(4):428-431. doi: 10.14412/1995-4484-2013-1255Eliseev MS, Barskova VG, Nasonov EL. Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(4):428-431 (In Russ.)]. doi: 10.14412/1995-4484-2013-1255So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10): 3064-3076. doi: 10.1002/art.27600So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10): 3064-3076. doi: 10.1002/art.27600Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther. 2011; 13(2):R53. doi: 10.1186/ar3297Schlesinger N, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther. 2011; 13(2):R53. doi: 10.1186/ar3297Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839-1848. doi: 10.1136/annrheumdis-2011-200908Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839-1848. doi: 10.1136/annrheumdis-2011-200908van Poppel PC, van Asseldonk EJ, Holst JJ, Vilsbøll T, Netea MG, Tack CJ. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16(12):1269-1273. doi: 10.1111/dom.12357van Poppel PC, van Asseldonk EJ, Holst JJ, Vilsbøll T, Netea MG, Tack CJ. The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes Obes Metab. 2014;16(12):1269-1273. doi: 10.1111/dom.12357Ruscitti P, Berardicurti O, Cipriani P, Giacomelli R; TRACK study group. Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: Long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. Clin Exp Rheumatol. 2021;39(2):403-406. doi: 10.55563/clinexprheumatol/phsqg7Ruscitti P, Berardicurti O, Cipriani P, Giacomelli R; TRACK study group. Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: Long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. Clin Exp Rheumatol. 2021;39(2):403-406. doi: 10.55563/clinexprheumatol/phsqg7Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Lioté F, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755-760. doi: 10.1016/j.jbspin.2018.03.015Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Lioté F, et al. Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine. 2018;85(6):755-760. doi: 10.1016/j.jbspin.2018.03.015Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of Interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol. 2020;76(14):1660-1670. doi: 10.1016/j.jacc.2020.08.011Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of Interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol. 2020;76(14):1660-1670. doi: 10.1016/j.jacc.2020.08.011Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-542. doi: 10.7326/M18-1167Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-542. doi: 10.7326/M18-1167Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M. Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol. 2022;111:109075. doi: 10.1016/j.intimp.2022.109075Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M. Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol. 2022;111:109075. doi: 10.1016/j.intimp.2022.109075
The authors declare that there are no conflicts of interest present.